Cambridge Investment Research Advisors’s Quest Diagnostics DGX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $3.28M | Buy |
15,492
+998
| +7% | +$196K | 0.01% | 1314 |
|
|
2026
Q1 | $2.84M | Buy |
14,494
+1,028
| +8% | +$200K | 0.01% | 1318 |
|
|
2025
Q4 | $2.34M | Buy |
13,466
+550
| +4% | +$100K | 0.01% | 1400 |
|
|
2025
Q3 | $2.46M | Buy |
12,916
+2,401
| +23% | +$426K | 0.01% | 1350 |
|
|
2025
Q2 | $1.89M | Buy |
10,515
+1,607
| +18% | +$279K | 0.01% | 1472 |
|
|
2025
Q1 | $1.51M | Buy |
8,908
+1,693
| +23% | +$278K | 0.01% | 1545 |
|
|
2024
Q4 | $1.09M | Buy |
7,215
+300
| +4% | +$46.7K | ﹤0.01% | 1806 |
|
|
2024
Q3 | $1.07M | Buy |
6,915
+118
| +2% | +$17.6K | ﹤0.01% | 1808 |
|
|
2024
Q2 | $930K | Sell |
6,797
-3,932
| -37% | -$538K | ﹤0.01% | 1825 |
|
|
2024
Q1 | $1.43M | Sell |
10,729
-74
| -0.7% | -$9.6K | 0.01% | 1482 |
|
|
2023
Q4 | $1.49M | Sell |
10,803
-378
| -3% | -$49.7K | 0.01% | 1391 |
|
|
2023
Q3 | $1.36M | Sell |
11,181
-25,544
| -70% | -$3.4M | 0.01% | 1373 |
|
|
2023
Q2 | $5.16M | Buy |
36,725
+28,953
| +373% | +$3.99M | 0.02% | 644 |
|
|
2023
Q1 | $1.1M | Sell |
7,772
-296
| -4% | -$42.3K | 0.01% | 1514 |
|
|
2022
Q4 | $1.26M | Sell |
8,068
-184
| -2% | -$26.4K | 0.01% | 1358 |
|
|
2022
Q3 | $1.01M | Sell |
8,252
-6,020
| -42% | -$793K | 0.01% | 1465 |
|
|
2022
Q2 | $1.9M | Buy |
14,272
+2,792
| +24% | +$380K | 0.01% | 1073 |
|
|
2022
Q1 | $1.57M | Sell |
11,480
-3,414
| -23% | -$476K | 0.01% | 1287 |
|
|
2021
Q4 | $2.58M | Sell |
14,894
-3,888
| -21% | -$592K | 0.01% | 1007 |
|
|
2021
Q3 | $2.73M | Buy |
18,782
+4,797
| +34% | +$702K | 0.01% | 917 |
|
|
2021
Q2 | $1.85M | Buy |
13,985
+318
| +2% | +$41.6K | 0.01% | 1168 |
|
|
2021
Q1 | $1.75M | Buy |
13,667
+3,572
| +35% | +$440K | 0.01% | 1081 |
|
|
2020
Q4 | $1.2M | Sell |
10,095
-1,177
| -10% | -$143K | 0.01% | 1188 |
|
|
2020
Q3 | $1.29M | Sell |
11,272
-35,316
| -76% | -$4.17M | 0.01% | 1036 |
|
|
2020
Q2 | $5.31M | Sell |
46,588
-7,849
| -14% | -$832K | 0.04% | 421 |
|
|
2020
Q1 | $4.37M | Buy |
54,437
+2,061
| +4% | +$213K | 0.04% | 405 |
|
|
2019
Q4 | $5.59M | Buy |
52,376
+4,497
| +9% | +$469K | 0.04% | 421 |
|
|
2019
Q3 | $5.12M | Buy |
47,879
+2,043
| +4% | +$210K | 0.05% | 391 |
|
|
2019
Q2 | $4.67M | Buy |
45,836
+2,457
| +6% | +$236K | 0.04% | 412 |
|
|
2019
Q1 | $3.9M | Buy |
43,379
+38,490
| +787% | +$3.34M | 0.04% | 456 |
|
|
2018
Q4 | $407K | Sell |
4,889
-32,850
| -87% | -$3.08M | ﹤0.01% | 1437 |
|
|
2018
Q3 | $4.07M | Buy |
37,739
+623
| +2% | +$68.3K | 0.04% | 433 |
|
|
2018
Q2 | $4.08M | Sell |
37,116
-536
| -1% | -$55.8K | 0.04% | 396 |
|
|
2018
Q1 | $3.78M | Buy |
37,652
+1,531
| +4% | +$157K | 0.04% | 394 |
|
|
2017
Q4 | $3.56M | Buy |
36,121
+3,359
| +10% | +$318K | 0.04% | 397 |
|
|
2017
Q3 | $3.07M | Sell |
32,762
-342
| -1% | -$36.3K | 0.04% | 403 |
|
|
2017
Q2 | $3.68M | Buy |
33,104
+3,719
| +13% | +$393K | 0.05% | 331 |
|
|
2017
Q1 | $2.88M | Buy |
29,385
+4,748
| +19% | +$453K | 0.05% | 347 |
|
|
2016
Q4 | $2.26M | Buy |
24,637
+5,967
| +32% | +$514K | 0.04% | 402 |
|
|
2016
Q3 | $1.58M | Sell |
18,670
-1,032
| -5% | -$86.7K | 0.03% | 499 |
|
|
2016
Q2 | $1.6M | Buy |
19,702
+9,800
| +99% | +$746K | 0.03% | 431 |
|
|
2016
Q1 | $708K | Sell |
9,902
-43
| -0.4% | -$2.88K | 0.02% | 721 |
|
|
2015
Q4 | $707K | Buy |
9,945
+1,121
| +13% | +$75.4K | 0.02% | 694 |
|
|
2015
Q3 | $542K | Sell |
8,824
-261
| -3% | -$18.2K | 0.02% | 723 |
|
|
2015
Q2 | $659K | Buy |
9,085
+221
| +2% | +$16.3K | 0.02% | 677 |
|
|
2015
Q1 | $681K | Sell |
8,864
-1,211
| -12% | -$86.7K | 0.02% | 652 |
|
|
2014
Q4 | $676K | Buy |
10,075
+807
| +9% | +$50.9K | 0.02% | 634 |
|
|
2014
Q3 | $562K | Buy |
9,268
+326
| +4% | +$20.1K | 0.02% | 770 |
|
|
2014
Q2 | $525K | Buy |
8,942
+386
| +5% | +$22.6K | 0.02% | 731 |
|
|
2014
Q1 | $496K | Buy |
+8,556
| New | +$459K | 0.02% | 717 |
|
Other funds holding DGX
EIG
Cambridge Investment Research Advisors's DGX Position: Q2 2026 in Review
Cambridge Investment Research Advisors increased its Quest Diagnostics (DGX) stake by 6.9% in Q2 2026, buying an estimated $196K and bringing the position to 15,492 shares worth $3.28M. The position accounts for 0.01% of the portfolio, ranked #1314.
Cambridge Investment Research Advisors first reported a position in DGX in Q1 2014 and has held it in 50 quarters since. The position peaked at $5.59M in Q4 2019. 1,099 funds tracked by Wall St. Rank hold DGX as of Q2 2026.
- Cambridge Investment Research Advisors held 15,492 shares of Quest Diagnostics worth $3.28M as of Q2 2026.
- Cambridge Investment Research Advisors bought 998 Quest Diagnostics shares in Q2 2026, an estimated $196K.
- Quest Diagnostics made up 0.01% of Cambridge Investment Research Advisors's portfolio in Q2 2026, its #1314 holding.
- Cambridge Investment Research Advisors first reported a position in Quest Diagnostics in Q1 2014 and has held it in 50 quarters since.
- Cambridge Investment Research Advisors's Quest Diagnostics position peaked at $5.59M in Q4 2019.
- 1,099 funds tracked by Wall St. Rank held Quest Diagnostics as of Q2 2026.
Based on Cambridge Investment Research Advisors's 13F filing for Q2 2026, filed 27 Jul 2026.